Company Research Report: Otsuka America Pharmaceutical, Inc.

Company Overview

• Name: Otsuka America Pharmaceutical, Inc. (OAPI)

• Mission: Otsuka is a healthcare company driven by the purpose of defying limitations to improve patient care and introduce innovative health solutions. Their mission includes creating new products for better health worldwide.

• Founded: Otsuka was founded in 1921 by Busaburo Otsuka in Tokushima Prefecture, Japan.

• Key People: Robert Murphy is the Senior Director of External Communications.

• Headquarters:

• 508 Carnegie Center Dr, Princeton, NJ 08540, United States

• 2440 Research Blvd, Rockville, MD 20850, United States

• 3956 Point Eden Way, Hayward, CA 94545, United States

• 30 Enterprise, Suite 200, Aliso Viejo, CA 92656, United States

• Number of Employees: OAPI and OPDC, as part of the Otsuka Holdings Co., Ltd family, contribute to over 45,000 employees globally across 28 countries.

• Revenue: No information is available.

• Known For: Otsuka is known for their innovative healthcare products, particularly in neuroscience, nephrology, oncology, and digital innovation.

Products

Neuroscience

• ABILIFY® (aripiprazole)

• High-level Description: A medication used in the treatment of several mental health disorders.

• Key Features: Available with full prescribing information including boxed warnings.

• ABILIFY ASIMTUFII® (aripiprazole) for extended release injectable suspension

• High-level Description: Extended-release version of aripiprazole for injection.

• Key Features: Comes with comprehensive prescribing information and a medication guide.

• ABILIFY MAINTENA® (aripiprazole) for extended release injectable suspension

• High-level Description: Used for long-term maintenance of certain mental disorders.

• Key Features: Available with detailed prescribing information and boxed warnings.

• NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) capsules

• High-level Description: A combination medication primarily for certain neurological conditions.

• Key Features: Available with full prescribing information.

• REXULTI® (brexpiprazole)

• High-level Description: Utilized for the treatment of major depressive disorder and schizophrenia.

• Key Features: Comes with full prescribing information and boxed warnings.

Digital Innovation

• ABILIFY MYCITE® (aripiprazole tablets with sensor)

• High-level Description: A tablet with a sensor to monitor medication adherence.

• Key Features: The world's first FDA-approved digital medicine, however, commercialization was discontinued in October 2024.

Nephrology

• JYNARQUE® (tolvaptan)

• High-level Description: Used for the treatment of certain kidney diseases.

• Key Features: Includes thorough prescribing information and boxed warnings.

• SAMSCA® (tolvaptan)

• High-level Description: Aimed at managing fluid balance in certain medical conditions.

• Key Features: Comes with comprehensive prescribing information and boxed warnings.

Oncology

• IV BUSULFEX® (busulfan)

• High-level Description: Used in the treatment of certain cancers.

• Key Features: Available with full prescribing information and boxed warnings.

Recent Developments

• New Report on Caregivers: A recent report sponsored by Otsuka reveals the equivalent economic value of U.S. family caregivers is a staggering $873.5 billion.

• Sibeprenlimab Phase 3 Trial: Otsuka announced positive interim results from the Phase 3 trial for Sibeprenlimab, a treatment for immunoglobulin A nephropathy in adults, showing significant promise.

• Mental Health America Collaboration: Otsuka collaborated with Mental Health America to address mental health inequities in New Jersey communities, launching a new Equity Impact Zone (EIZ) grant program.

• Collaboration with Barbara Corcoran: Otsuka collaborated with Barbara Corcoran to raise awareness of agitation in Alzheimer’s dementia through the national campaign ‘I Wish I Knew.’

No specific new product launches or new features to existing products outside the discontinuation of ABILIFY MYCITE® are noted.

This report provides a comprehensive view of Otsuka America Pharmaceutical, Inc.’s current status based on the available data, highlighting its significant presence in the healthcare innovation space.